Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin for Post-Transplant Complications
NCT06801886Phase 3Enrolling by invitation
- Sponsor
- University Hospital Martin
- Start
- Jan 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in kidney transplant rejection, diabetes mellitus (DM) and primary graft dysfunction (PGD) comparing Silymarin Arm with Placebo Arm (2 arms). Primary endpoints: Estimated Glomerular Filtration Rate improvement at 3 months and Incidence of biopsy proven acute rejection at 6 months. Started Jan 2020; status: enrolling by invitation.
02
Drugs
silymarin
03
Conditions
kidney transplant rejectiondiabetes mellitus (DM)primary graft dysfunction (PGD)
Beyond the preview
Go deeper on NCT06801886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801886.